INR 119.02
(2.24%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.41 Billion INR | -43.6% |
2022 | 2.51 Billion INR | 9.94% |
2021 | 2.28 Billion INR | 53.83% |
2020 | 1.48 Billion INR | 15.98% |
2019 | 1.28 Billion INR | 12.51% |
2018 | 1.14 Billion INR | 40.33% |
2017 | 812.56 Million INR | -69.55% |
2016 | 2.66 Billion INR | 92.45% |
2015 | 1.38 Billion INR | 0.89% |
2014 | 1.37 Billion INR | 21.13% |
2013 | 1.13 Billion INR | 29.73% |
2012 | 874.67 Million INR | 239.63% |
2011 | 257.53 Million INR | -29.08% |
2010 | 363.15 Million INR | 19.05% |
2009 | 305.03 Million INR | 48.08% |
2008 | 205.99 Million INR | -2.77% |
2007 | 211.86 Million INR | 5.14% |
2006 | 201.5 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 376.33 Million INR | -24.43% |
2024 Q2 | 682.58 Million INR | -10.26% |
2023 Q3 | 614.91 Million INR | -4.17% |
2023 Q1 | 570.7 Million INR | -23.33% |
2023 FY | 1.41 Billion INR | -43.6% |
2023 Q4 | 498 Million INR | -19.01% |
2023 Q2 | 641.64 Million INR | 12.43% |
2022 Q2 | 567.1 Million INR | -4.18% |
2022 Q4 | 744.36 Million INR | 21.47% |
2022 FY | 2.51 Billion INR | 9.94% |
2022 Q1 | 591.85 Million INR | 57.58% |
2022 Q3 | 612.81 Million INR | 8.06% |
2021 Q4 | 375.58 Million INR | -50.11% |
2021 Q1 | 511.18 Million INR | 55.2% |
2021 FY | 2.28 Billion INR | 53.83% |
2021 Q2 | 649.17 Million INR | 26.99% |
2021 Q3 | 752.78 Million INR | 15.96% |
2020 Q2 | 426.62 Million INR | 22.16% |
2020 Q1 | 349.22 Million INR | 32.67% |
2020 FY | 1.48 Billion INR | 15.98% |
2020 Q4 | 329.37 Million INR | -13.91% |
2020 Q3 | 382.6 Million INR | -10.32% |
2019 Q4 | 263.21 Million INR | -27.57% |
2019 Q1 | 333 Million INR | 83.1% |
2019 Q2 | 323.25 Million INR | -2.93% |
2019 Q3 | 363.39 Million INR | 12.42% |
2019 FY | 1.28 Billion INR | 12.51% |
2018 FY | 1.14 Billion INR | 40.33% |
2018 Q3 | 319.62 Million INR | -2.5% |
2018 Q4 | 181.86 Million INR | -43.1% |
2018 Q2 | 327.81 Million INR | 16.64% |
2018 Q1 | 281.04 Million INR | -46.97% |
2017 Q4 | 530 Million INR | -27.33% |
2017 FY | 812.56 Million INR | -69.55% |
2017 Q2 | 433.56 Million INR | -16.52% |
2017 Q1 | 519.37 Million INR | -42.84% |
2017 Q3 | 729.3 Million INR | 68.21% |
2016 Q1 | 299.41 Million INR | 70.92% |
2016 FY | 2.66 Billion INR | 92.45% |
2016 Q4 | 908.65 Million INR | 43.46% |
2016 Q3 | 633.37 Million INR | 10.82% |
2016 Q2 | 571.52 Million INR | 90.88% |
2015 Q2 | 451.79 Million INR | 96.35% |
2015 FY | 1.38 Billion INR | 0.89% |
2015 Q4 | 175.17 Million INR | -74.38% |
2015 Q3 | 683.66 Million INR | 51.32% |
2015 Q1 | 230.09 Million INR | 0.0% |
2014 FY | 1.37 Billion INR | 21.13% |
2013 FY | 1.13 Billion INR | 29.73% |
2012 Q4 | 586 Million INR | 329.8% |
2012 FY | 874.67 Million INR | 239.63% |
2012 Q1 | 53.18 Million INR | 0.0% |
2012 Q2 | 99.14 Million INR | 86.42% |
2012 Q3 | 136.34 Million INR | 37.52% |
2011 FY | 257.53 Million INR | -29.08% |
2010 FY | 363.15 Million INR | 19.05% |
2009 FY | 305.03 Million INR | 48.08% |
2008 FY | 205.99 Million INR | -2.77% |
2007 FY | 211.86 Million INR | 5.14% |
2006 FY | 201.5 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 91.057% |
Hester Biosciences Limited | 908.84 Million INR | -56.158% |
Aarti Drugs Limited | 1.16 Billion INR | -21.563% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 53.837% |
Albert David Limited | 1.02 Billion INR | -38.306% |
Alembic Limited | 872.45 Million INR | -62.669% |
Alkem Laboratories Limited | 32.83 Billion INR | 95.678% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | -211.516% |
Bajaj HealthCare Limited | 985.34 Million INR | -44.033% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -20709.707% |
Brooks Laboratories Limited | 51.18 Million INR | -2673.001% |
Eris Lifesciences Limited | 4.94 Billion INR | 71.288% |
FDC Limited | 3.49 Billion INR | 59.448% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 87.808% |
Gufic Biosciences Limited | 1.18 Billion INR | -19.605% |
Hikal Limited | 4.46 Billion INR | 68.206% |
Ind-Swift Limited | 946.56 Million INR | -49.934% |
Innova Captab Limited | 931.03 Million INR | -52.436% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 35.519% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -223.617% |
Jubilant Pharmova Limited | 14.45 Billion INR | 90.181% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -32.121% |
Lupin Limited | 125.09 Billion INR | 98.865% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -774.832% |
Medico Remedies Limited | 59.67 Million INR | -2278.252% |
Morepen Laboratories Limited | 1.98 Billion INR | 28.591% |
Nectar Lifesciences Limited | 932.7 Million INR | -52.163% |
Orchid Pharma Limited | 800.77 Million INR | -77.232% |
Procter & Gamble Health Limited | 2.99 Billion INR | 52.62% |
RPG Life Sciences Limited | 1.63 Billion INR | 13.224% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -244.115% |
Sigachi Industries Limited | 579.88 Million INR | -144.741% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 44.434% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | -1.171% |
Themis Medicare Limited | 1.12 Billion INR | -26.064% |
Unichem Laboratories Limited | 6.72 Billion INR | 78.899% |
Vaishali Pharma Limited | 84.02 Million INR | -1588.967% |
Wanbury Limited | 978.96 Million INR | -44.972% |
Windlas Biotech Limited | 1 Billion INR | -41.004% |
ZIM Laboratories Limited | 1.01 Billion INR | -40.093% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 33.187% |
Ipca Laboratories Limited | 18.98 Billion INR | 92.526% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.08% |
Venus Remedies Limited | 1.91 Billion INR | 25.939% |
Sakar Healthcare Limited | 204.07 Million INR | -595.428% |
Aurobindo Pharma Limited | 55.65 Billion INR | 97.45% |
Divi's Laboratories Limited | 14.17 Billion INR | 89.984% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 42.623% |
Mankind Pharma Limited | 29.27 Billion INR | 95.152% |
Sequent Scientific Limited | 2.9 Billion INR | 51.092% |
Laurus Labs Limited | 11.9 Billion INR | 88.084% |
Neuland Laboratories Limited | 2.92 Billion INR | 51.558% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 90.406% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 96.977% |
Zydus Lifesciences Limited | 125.21 Billion INR | 98.867% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 32.226% |
Wockhardt Limited | 8.48 Billion INR | 83.264% |
Bal Pharma Limited | 555.62 Million INR | -155.428% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.52% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -2334.843% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 34.733% |
Shilpa Medicare Limited | 3.33 Billion INR | 57.434% |
Valiant Laboratories Limited | 138.02 Million INR | -928.206% |
Ajanta Pharma Limited | 30.46 Billion INR | 95.341% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -9885.38% |
Granules India Limited | 10.31 Billion INR | 86.238% |
Medicamen Biotech Limited | 335.16 Million INR | -323.437% |
Syncom Formulations (India) Limited | 345.63 Million INR | -310.615% |
Piramal Enterprises Limited | 63.65 Billion INR | 97.77% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 93.375% |
NATCO Pharma Limited | 10.05 Billion INR | 85.89% |
Suven Life Sciences Limited | 109.75 Million INR | -1193.141% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2974.838% |
Strides Pharma Science Limited | 9.16 Billion INR | 84.51% |
Indoco Remedies Limited | 12.06 Billion INR | 88.233% |
Alpa Laboratories Limited | 127.38 Million INR | -1014.164% |
Lasa Supergenerics Limited | 291.17 Million INR | -387.414% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 53.873% |